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CARDIACPROTEINRGS2: STRUCTURALANDFUNCTIONALDETERMINANTS
Advisor-Dr.
Brett Adams, Department of Biology, Utah State University

INTRODUCTION:
In this study, I explored the structure-function relationships of a cardiac RGS (regulator
of G-protein signaling) protein, RGS2.
Contractions of the heart are triggered by calcium ions (Ca) entering heart cells through
L-type Ca channels (1a). The activity of L-type channels (and thereby Ca influx) is modulated
by cell surface receptors that couple to intracellular G proteins. G proteins in turn, are regulated
by a newly-discovered family of proteins called RGS. RGS proteins speed the hydrolysis of
GTP by G proteins, and thereby control the strength and duration of G protein-mediated signals.
Stimulation of G proteins, which are coupled to receptors , can alter the rate of heart contractions
(2).
Contraction rate of heart cells is important for several reasons. Namely, a slower,
controlled contraction rate, or heartbeat, pumps oxygenated blood throughout the body more
efficiently than a fast contraction rate. It has been shown that inadequate blood flow through the
heart is directly correlated with deficiency of calcium channel stimulation (lb). Several RGS
proteins are expressed in heart, but their physiological significance and ability to affect influx of
calcium ions through calcium channels has been largely unexplored. This study reveals new
insights into the structure /function relationships of RGS2. These insights may be helpful m
understanding the molecular basis of certain cardiovascular diseases.
DETAILEDEXPLANATION:
Proteins in the RGS2 family are composed of a highly conserved core region and variable
terminal regions (3). My major objective was to determine the functional importance of the
RGS2 non-core regions (N-terminus and C-terminus).
I used the polymerase chain reaction
(PCR) to construct mutant RGS2 proteins lacking the amino-tenninus, the carboxyl-terminus, or
both. These mutant RGS2 proteins were expressed in a cell line and their abilities to influence
L-type Ca channel activity were determined via electrophysiological experiments. RGS proteins
speed up the rate of GTP hydrolysis by 100-fold, the inhibition of extracellular calcium should
decrease the rate of heart contraction . Thus , we expected their presence to inhibit the influx of
extracellular calcium into the cell.
Cell culture methods were employed to maintain mammalian HEK293 cells for
transfection with normal RGS2 and RGS2 core. Cardiac calcium current was measured via
patch-clamp recording.
Patch-clamp recording was used to measure whole-cell Ca channel
currents and current inhibition during activation of coexpressed M 1 muscarinic acetylcholine
receptors . Through the use of specifically designed oligonucleotide primers, we amplified only
the core region of RGS2. The primers contained restriction enzyme sites to facilitate insertion of
the RGS2 core into an expression vector. The PCR product was gel purified and digested with
restriction enzymes corresponding to the primer enzyme sites. The digested PCR product was
then ligated into the bicistronic mammalian expression vector pIRES-2, which independently
expresses green fluorescent protein as a transfection marker. Alternatively, transfected cells
were identified by cotransfection with an expression plasmid encoding the cell surface antigen
CD8. We found that RGS2 prevents channel inhibition by Ml receptors, and that the RGS2 core
3

does not prevent channel inhibition. Thus, structural regions flanking RGS2 core are required
for proper function of RGS2. The functional importance of other structural regions of RGS2 are
presently being analyzed.
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OTHER IMPORTANT WORK WITH DR. BRETT ADAMS:

From a summer research program during high school, I was able to gain a familiarity with basic
lab procedures. This allowed me to begin meaningful work as an assistant in various projects
once I began in Dr. Adams' lab as a freshman at Utah State University. My work included
animal dissection of adult and neonatal organs (i.e., heart ventricle and dorsal root ganglia) and
establishing primary cell cultures from these organs. My work also entailed various basic
procedures such as purifying DNA, growing bacterial cultures, etc.
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II TRANSCRIPTION FACTOR OF APOLIPOPROTEIN B
Joan Hevel, Depa1tment of Chemistry & Biochemistry, Utah State University
PROTEIN

Advisor-Dr.
INTRODUCTION:

Protein involvement in human disease is on the forefront of proteomic research. Proteins
are involved in a multitude of mammalian cellular processes. Structure-function relationships
govern the responsibilities of both structural and enzymatic proteins. Advancement in proteomic
research over the past five years has enabled researchers to begin ascribing function to the
extensive array of human proteins. Understanding these functions is critical to determining
variation in protein function when the cellular environment is in a diseased, stressed, or
cancerous state. It is especially important to detern1ine what causes proteins themselves to
trigger disease.
Medical researchers are now implicating specific proteins in leading to cardiovascular
disease (CVD) ( 1). CVD has become an umbrella-term for the myriad of problems that develop
in the vascular system due to its domino-effect of decreasing the efficiency of other organs. This
makes treatment very difficult as the disease progresses and is one reason CVD has become an
epidemic in the United States. Cholesterol deposition is one main cause of CVD in humans.
LDL (Low-Density Lipoprotein) is one of the main components involved in causing cholesterol
deposition. My interest has been in studying LDL, whose main component is ApoB
(Apoliprotein B). Transcription of ApoB takes place when transcription factors bind to DNA
encoding the specific gene. These transcription factors are protein molecules which possess
consensus sequences for binding to DNA. It is hoped that understanding protein-DNA
interactions that trigger synthesis of harmful molecules will lead to measures of therapeutic
intervention. Because ApoB can only be synthesized after the action of sequence-specific DNAbinding proteins, my specific goal has been to identify the second of three binding proteins
necessary for transcription of ApoB. (The first and third binding proteins are already known.)
This project is being currently being pursued under the supervision of Dr. Joan Hevel,
Department of Chemistry and Biochemistry, Utah State University. Hopefully, therapeutic
strategies may be developed in response to present research in proteomics.
DETAILED EXPLANATION:

DLD (Low-Density Lipoprotein) transports cholesterol in the blood; high levels of blood
LDL are correlated to risk of heart disease (2). LDL's lipid/protein structure contains a major
component-Apolipoprotein B (ApoB). Because ApoB is a precursor to LDL synthesis, it is
confirmed that blood levels of ApoB are a better predictor of cardiovascular disease (CVD) risk
than LDL blood levels (for which millions of Americans are currently screened every year) (3).
Production of ApoB requires transcription of the ApoB gene. Transcription, like many
biological processes, involves the action of sequence-specific DNA-binding proteins. In the case
of ApoB, there are three binding proteins; two known (HNF I-alpha, C/EBP) and one unknown
(called "Protein II"). The binding sites for these three proteins are located on the core enhancer
of the ApoB gene. Essentially, these proteins act as gatekeepers to beginning the synthesis of
ApoB. They must be bound to thefr respective binding sites on the enhancer for transcription of
ApoB to occur. It has been shown that binding HNF-1-alpha is necessary for full activity of the
ApoB enhancer in HepG2 cells; wlhen HNF I-alpha binding does not occur, activity of the core
enhancer decreases by 80% (4). Itt was also shown that binding of C/EBP is necessary for full
5

activity of the enhancer. Mutagenesis of HNF-1 alpha and/or C/EBP binding sites shows that
binding of both these proteins is essential for full ApoB gene expression (5). The third
component necessary for full activity of the core enhancer , Protein II, remains relatively
unexplored. Disruption of Protein II binding also diminishes the capacity of enhancer activity.
Although work has been done to identify both proteins HNF-lalpha and C/EBP, the identity of
Protein II is yet to be discovered. Currently, my work seeks to 1) design an affinity resin based
on the sequence that binds Protein II (via DNA affinity chromatography); 2) purify protein II
using the designed affinity resin; and, 3) characterize Protein II by mass spectrometry to discern
the identity and perhaps the specific function of Protein II in enhancing transcription of ApoB.
Using the DNA sequence of the Protein II binding site, we will design a sequence-based affinity
resin using an established method (6). The designed affinity resin will allow us to isolate Protein
II from a mixture of several proteins in HepG2 cells. Protein II can then be enzymatically
digested to obtain its peptide components and characterized using mass spectrometry. Data from
the mass spectral analysis will be used to perform database searchers to identify Protein II. After
the identity of Protein II is known, we will classify the functional regions of the protein in order
to discern how its binding to the enhancer region of ApoB increases transcription of ApoB.
Because transcription of the ApoB gene s regulated in a tissue-specific manner, this project will
also provide insights into the regulation of tissue-specific gene expression.
My results will increase understanding of structure-function relationships in order to
eventually control synthesis of ApoB through the use of specifically designed antagonist
molecules. These results will also increase our understanding of how levels of LDL are
regulated in the body , leading to better understanding of what causes proteins to initiate synthesis
of harmful molecules.
Through continued research into protein biochemistry, I hope to contribute to our current
knowledge of cardiovascular health.
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OTHER IMPORTANT WORK WITH DR. JOAN HEVEL:

I have established a room for tissue culture within our research facility. My work has involved
each step of the process-from design layout and ordering equipment to the actual culturing of
cells. This working facility will soon serve five researchers in projects involving A549 lung cells
in tissue culture experiments.
Recently, my work with Dr. Hevel has explored the role of PRMT6 (Protein Arginine
Methylation) in apoptosis induction via RNAi experiments. This work is detailed in the
following poster presentation (Student Showcase 2005).
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Cardiac RGS Protein Structural Determinants and Function
Stephanie Chambers , Roger Bannister and Brett Adams
Department of Biology, Utah State University, Logan, UT 84322
Introduction

Polymerase Chain Reaction

Figure 4. HEK293 cells and patch-clamp pipette

Contractionsof n,, h.. n ,,.. tr1gg,rtd by calciumk)n1(Ca) ,nt,rtng h11rt
etlll lhrollgh L-type C ■ ch-,v,111. The activity ofL-type channels (and
lhtreby C1 lnftu)()11modulated t,y c• • 1urf1u r,c,ptor1 that couple to

lntr1c,nu11rmo11cul1r
l'Mlches knownas ·o prot11n1
· (.Tor
OTP-binding
protein). G prol1tn1, In lum . art regulated by I newt)'-dlscov,,.d family o/
prol1tn1 Clllld RGS (tor [t9Uletor of 2 prol.in 11gn1llng). RGS proteins
&pHd lht hydrolylls of OTP by G prot.ins , tl'ld thereby conlrol lM sl!'fflglh
and dlntlon of G prottln-m1dlat1d Signals.
RGS proltlnl ....
9X?fHHd In hHrt , bu! their physlologlcal slgn~tnct 11currtnll)' unknown .
In !ht prtunt study, we uplored !ht structurtA\mctlon
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chain rHctlon (PCR)
lo construct mutant RGS2 proteinsltc:klng!hf 1mlno-twmlnu1 , Iha
carb~l1rmlnu1 , or both. ThtH mutant RGS2 pl'Qteln1wel'I exp1"11HdIn
• cell line Ind lhllr lblUtlH to lnftu,nc, L·typl Cl ehennel •ctMty wtr•
determinedIn elect~lologlcal
ex~ment1 . TNt study rew1t1 ntw
lnllghtl Into the stNctur"1\lnctlon r,11t1on1hlp1of RGS2. These ln1lgh11
may be helpl\ll In i.mderllandlng th• molecular b11t1 oJc,rtllln
cardlov11cu11rdlHHH .
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Figure 6. Electrophyslologlcal Results
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Figure 2. Gel Purification of PCR product
PCBrnlt Plctm1110 :
Each or30 eyelet con11st1dof 1
minute 111
915°c lo allow
separation of ONAllr1nds .
followed by 1 minute It 155°c to
,How primersto anneal to
template, followed by 1 minute II
72 °c to allow eldentlon of new
ONA strands.
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Materials& Methods
•Ollgonucleotta, pnm,rs wert dHlgned to amplify only the col'I region of
RGS2. Thi p,1mers conl1lnld restriction •nZ)'ffle sites to fllcHNll• lnurtlon
or the R.GS2cort Into 1n exprHllon wctor .
•Thi potym,..... chain reaction (PCR) Ml
region.

UHd to amplty the RGS2 core

• Th• PCR.product wes gel purified end digested wllh restrk:tlon enzymes
corT9spondlnglo the primer enzyme snes. Th• digested PCR.product was
thin DgatedInto th, blclllronlc m1mmllllen 1xpr11slonvectorptRES-2
(Clont,ch), which tndep.ndenlty expr11s11grHn fluorescent protein 11 •
lr■n1flctlon marker. Altem10vety, lr1n1flcted cells wtr• ldenll\ld by
cotr■ nlf'ec:Uon with an expr11slonplesmld encoding tht cell slM'fec, 1nt'91n
coe c, .g. Fig. 4)
• Call cUllurt methods wtrt employt,d lo m1lnllln m1mm1ll1nHEK293 c1H1
ror trantfedlon wllh RGS2 Ind RGS2 core.
• PIich-Ciamp recording WH UHd lo fflH1ur, 'MlO,.ctl c, channal
CUrT'9nlS
end CUrT'9nl
Inhibition dur1ng1ctlvetlon of co,xprHHd M1
mu1c1rtnlcacetytchoUn, r9ceptors.
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conciuslona
& FutureExceriments
• RGS2 prewnts ch.wlel lnhlblllon Dy M1 rec1ptot1.
• RGS2 cora doet not prevenl channel lnl'llbltlon.
• Thul , structural regions nanldngRGS2 core are required for proper l\lnctlon of
R.GS2.
•Th• ft.mctlonll lmpo,tanc, of other slt\lcturel regions of RGS2 are preHntly being
1nllyzed .
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Biochemistry Classifieds : Stealthy RNAi Seeking Att ractive PRMT6
Stephanie J. Chambers, Department of Biology, Utah State University
Joan M. Hevel, Department of Chemistry & Biochemistry, Utah State University
Introduction
The central dogma of llclence (one gene encodes lnfonnat lon for one protein ,
one protein perfonns one function) is changing as we clarify the role of post•
trans1atlonat modifications (PTMs) . PTMs are changes to protein structure after
assembly by the ribosome . PTMs allow an organism to expand Its functlonal
proteome ; I.e ., create more function from a single gene . ?TM-dependent change
In prote in f\.nctlon can dictate molecular messages In cellular signa Ung
pathways . One class of enzymes that perfonns FTMs ls PRMT (Rroteln 1rglnlne
fl)ethyltransferase) , which catalyms the methy\at1onof specl11cpeptldyl arginine

HrnlJtJ
Figure 2. Weslern Blot Results from 12-Well Experiment

Figure 3. Human Lung Carcinoma A&48 Cell

Probed wlh anU-PRMT6
lmmunoftuorescent
labeling shows eel
focal
adhesion
sites
(green) ,
protein complexes
that anchor cens to
the
extracelhJar
matrix.

1415

residues In select proteins.
Our laboratory is currentty studying the
methylarginine proteome of human A549 lung epllheHal cens In order to
understand how each of the 8 human PRMTs may be Involved In cellular
communication .

~
Knock·do'wn expression of PRMT6 protein using RNA interference In human
lung AS-48 eplthetial ceRs. Cen lysates 'MAbe assessed for a) the presence of
PRMT6 mRNA , b) PRMT6 protein and c) any altered change In the pattem of
protein arginine methylallon . We hope to Identify which proteins are methylated
by PRMT6 by comparing the methylargin lne proteome of control and RNAJ·
treated cells .

M!lll.odl

ln our research , we performed an RNAi ([iboouclelc 1.cld interference )
experiment to knock•down PRMT6 express ion In human AS-49 epithelia l tung
cells (See Figure 3). Introduction of double.stranded RNA (red/blue strand ) Into
cells can suppress gene express ion
by
target ing
specific
mRNA
Figure 1. RNAJMechanism
sequences for degradation .
The
genera l mechanism by 'Which this
occurs is shown In Figure 1 at left .
stealthRNAi molecules (lnvitrogen )
were designed against PRMT6 based
on pre"1ous protocols and use of
lnvlt rogen 's o~Hne design program .
lipofectamlne 2000 was used as a
vehi cle
to
suspend
the
RNAI
molecules and to aid In the uptake of
ONA Into the ceNs. Antibodies to
PRMT6
were
purchased
from
lmmunige nex .
Human AS-49 lung
epithe lial ce0s were cultured In a
12•weH plate .
Cens at 50-60%
confluency were treated with either
media , lipofectamlne
2000 , Stealth
RNAi or a scrambled Stealth RNAi
molecule as a negative contro l as
depicted in Figure 2 .
Cells were
harvested after 72 hours of treatment ,
a soluble prote in lysate prepared , and
the presence of PRMT6 assessed by
West.em analysi s .

A

B

C

fgggl

m

8. RNAI A - Media+ RNA Vehicle+ RNAI
12-W•IPID
g RNAI B - Media+ RNA Vehicle+ RNAI
10. RNAJC - Media+ RNA Vehkle + RNAI
11. Scrambled A - Media+ RNA Vehicle+ Scrambled RNA.I
12. Scrambled B - Media+ RNA Vehlcle + Scrambled RNAI
13· Scrambled C - Media+ RNA Vehicle+ Scrambled RNA.I
1, . Control D - Cytoplasmic tysate
15• Marker

Resutts
& Conclu,1001
• Given the current conditions , PRMT6 protein levels did
change in A5-49 eels .

not appear to

FutureExperiments
• Asses the abiUty of the c1.1Tentconditions to decrease leve ls of PRMT6

mRN.._
,
• Optimize cond itions for effective PRMT6 prote in knock•down .
• Assess changes In methylatlon
knockdown expe riments .

patterns

tn the ceU after

RNAI

• Assess phenotypic changes of PRMT6 knockdowns .
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